Harmony Biosciences Holdings, Inc. cash flow to debt ratio of 145.34% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Harmony Biosciences Holdings, Inc.'s free cash flow has increased 59.09% from $218.67M last year to $347.89M, signaling increasing performance

Harmony Biosciences Holdings, Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability.

Harmony Biosciences Holdings, Inc.'s debt has decreased relative to shareholder equity from 0.28 last year to 0.15 today, signaling strengthened financials

Harmony Biosciences Holdings, Inc. has a net cash position, so leverage is healthy.

Harmony Biosciences Holdings, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Harmony Biosciences Holdings, Inc.'s profit margin has decreased (7.23%) in the last year from 20.36% to 18.88%, signaling decreasing performance

Harmony Biosciences Holdings, Inc.'s short-term assets of $907.01M exceed its short-term liabilities of $252.13M

Harmony Biosciences Holdings, Inc.'s return on assets of 13.20% is higher than the 5.00% threshold, indicating efficient asset utilization

Harmony Biosciences Holdings, Inc.'s return on equity of 20.06%, is higher than 15.00%, indicating good performance

Harmony Biosciences Holdings, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Harmony Biosciences Holdings, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Harmony Biosciences Holdings, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Harmony Biosciences Holdings, Inc. has a free cash flow yield of 15.41%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Harmony Biosciences Holdings, Inc.'s yearly earnings has increased 9.07% since last year from $145.49M to $158.69M, signaling increasing performance

Harmony Biosciences Holdings, Inc.'s yearly revenue has increased 21.51% since last year from $714.73M to $868.45M, signaling increasing performance

ROIC 14.96% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Harmony Biosciences Holdings, Inc.'s 3-year revenue CAGR of 25.64% is positive, indicating growing revenue over the past 3 years

Harmony Biosciences Holdings, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Harmony Biosciences Holdings, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Harmony Biosciences Holdings, Inc. has insufficient data to evaluate this check.

Harmony Biosciences Holdings, Inc. has an earnings yield of 8.03%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Harmony Biosciences Holdings, Inc. is undervalued relative to its fair value price of 39.74 based on EBITDA multiple model

Harmony Biosciences Holdings, Inc. has an EV/EBITDA ratio of 6.75x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Harmony Biosciences Holdings, Inc. has insufficient data to evaluate this check.

Harmony Biosciences Holdings, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Harmony Biosciences Holdings, Inc. has a price-to-book ratio of 2.26x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Harmony Biosciences Holdings, Inc. has a price-to-sales ratio of 2.35x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue